Table 1.
Patient Sociodemographic and Treatment Characteristics, Glioblastoma, and National Cancer Database 2004–2014
| Characteristic | Overall, N = 93 477a | White Non-Hispanic, N = 81 900a | Black Non-Hispanic, N = 5124a | Asian Non-Hispanic, N = 1638a | Hispanic, N = 4815a | P valueb |
|---|---|---|---|---|---|---|
| Facility type | <.001 | |||||
| Academic/Research Program | 38 877 (44%) | 33 806 (43%) | 2422 (51%) | 774 (53%) | 1875 (43%) | |
| Community Cancer Program | 5262 (5.9%) | 4695 (6.0%) | 218 (4.6%) | 80 (5.4%) | 269 (6.2%) | |
| Comprehensive Community Cancer Program | 34 976 (39%) | 31 549 (40%) | 1416 (30%) | 497 (34%) | 1514 (35%) | |
| Integrated Network Cancer Program | 10 161 (11%) | 8723 (11%) | 660 (14%) | 117 (8.0%) | 661 (15%) | |
| Unknown | 4201 | 3127 | 408 | 170 | 496 | |
| Age | 64 (55–73) | 64 (56–73) | 60 (51–69) | 61 (50–70) | 60 (50–70) | <.001 |
| Sex | .001 | |||||
| Female | 39 748 (43%) | 34 796 (42%) | 2279 (44%) | 715 (44%) | 1958 (41%) | |
| Male | 53 729 (57%) | 47 104 (58%) | 2845 (56%) | 923 (56%) | 2857 (59%) | |
| Primary payor | <.001 | |||||
| Medicaid | 5279 (5.8%) | 3486 (4.4%) | 704 (14%) | 218 (14%) | 871 (19%) | |
| Medicare | 40 527 (44%) | 36 811 (46%) | 1810 (36%) | 480 (30%) | 1426 (31%) | |
| Not insured | 3433 (3.8%) | 2346 (2.9%) | 368 (7.4%) | 133 (8.3%) | 586 (13%) | |
| Other government | 1438 (1.6%) | 1245 (1.6%) | 130 (2.6%) | 19 (1.2%) | 44 (0.9%) | |
| Private insurance | 40 523 (44%) | 36 066 (45%) | 1989 (40%) | 756 (47%) | 1712 (37%) | |
| Unknown | 2277 | 1946 | 123 | 32 | 176 | |
| Urban/rural | <.001 | |||||
| Metro | 73 567 (82%) | 63 222 (81%) | 4424 (89%) | 1531 (98%) | 4390 (95%) | |
| Rural | 1727 (1.9%) | 1656 (2.1%) | 52 (1.1%) | 4 (0.3%) | 15 (0.3%) | |
| Urban | 14 075 (16%) | 13 354 (17%) | 471 (9.5%) | 31 (2.0%) | 219 (4.7%) | |
| Unknown | 4108 | 3668 | 177 | 72 | 191 | |
| Charlson–Deyo score | <.001 | |||||
| 0 | 67 094 (72%) | 59 159 (72%) | 3364 (66%) | 1188 (73%) | 3383 (70%) | |
| 1 | 16 055 (17%) | 13 898 (17%) | 1050 (20%) | 257 (16%) | 850 (18%) | |
| 2 | 6985 (7.5%) | 6020 (7.4%) | 453 (8.8%) | 128 (7.8%) | 384 (8.0%) | |
| 3 | 3343 (3.6%) | 2823 (3.4%) | 257 (5.0%) | 65 (4.0%) | 198 (4.1%) | |
| Surgical resection | <.001 | |||||
| Biopsy | 9306 (23%) | 8078 (23%) | 520 (22%) | 183 (21%) | 525 (23%) | |
| Gross total | 12 448 (30%) | 10 885 (31%) | 692 (29%) | 239 (28%) | 632 (28%) | |
| None | 8827 (22%) | 7653 (22%) | 529 (22%) | 201 (23%) | 444 (20%) | |
| Subtotal | 10 297 (25%) | 8790 (25%) | 621 (26%) | 235 (27%) | 651 (29%) | |
| Unknown | 52 599 | 46 494 | 2762 | 780 | 2563 | |
| Focality | .11 | |||||
| Multifocal | 7562 (19%) | 6549 (19%) | 403 (17%) | 164 (19%) | 446 (20%) | |
| Unifocal | 32 521 (81%) | 28 173 (81%) | 1906 (83%) | 690 (81%) | 1752 (80%) | |
| Unknown | 53 394 | 47 178 | 2815 | 784 | 2617 | |
| Readmission | <.001 | |||||
| Not readmitted | 85 183 (94%) | 74 778 (94%) | 4568 (92%) | 1476 (94%) | 4361 (93%) | |
| Readmitted | 5182 (5.7%) | 4376 (5.5%) | 376 (7.6%) | 101 (6.4%) | 329 (7.0%) | |
| Unknown | 3112 | 2746 | 180 | 61 | 125 | |
| Radiation | <.001 | |||||
| Not received | 27 851 (30%) | 24 214 (30%) | 1560 (31%) | 472 (29%) | 1605 (34%) | |
| Received | 65 128 (70%) | 57 266 (70%) | 3534 (69%) | 1152 (71%) | 3176 (66%) | |
| Unknown | 498 | 420 | 30 | 14 | 34 | |
| Chemotherapy | <.001 | |||||
| Not received | 31 547 (35%) | 27 247 (34%) | 1944 (40%) | 542 (35%) | 1814 (40%) | |
| Received | 59 100 (65%) | 52 338 (66%) | 2960 (60%) | 1027 (65%) | 2775 (60%) | |
| Unknown | 2830 | 2315 | 220 | 69 | 226 | |
| 30-day mortality | .017 | |||||
| Alive | 65 610 (95%) | 57 416 (95%) | 3562 (95%) | 1164 (97%) | 3468 (95%) | |
| Dead | 3587 (5.2%) | 3163 (5.2%) | 204 (5.4%) | 39 (3.2%) | 181 (5.0%) | |
| Unknown | 24 280 | 21 321 | 1358 | 435 | 1166 | |
| 90-day mortality | <.001 | |||||
| Alive | 58 095 (84%) | 50 716 (84%) | 3204 (86%) | 1070 (90%) | 3105 (86%) | |
| Dead | 10 859 (16%) | 9694 (16%) | 540 (14%) | 121 (10%) | 504 (14%) | |
| Unknown | 24 523 | 21 490 | 1380 | 447 | 1206 | |
| Survival months | 9 (3–18) | 9 (3–18) | 10 (4–20) | 12 (4–24) | 10 (4–21) | <.001 |
| Unknown | 4 | 3 | 0 | 0 | 1 | |
| Vital status | <.001 | |||||
| Alive | 9985 (11%) | 7836 (9.6%) | 751 (15%) | 331 (20%) | 1067 (22%) | |
| Dead | 83 492 (89%) | 74 064 (90%) | 4373 (85%) | 1307 (80%) | 3748 (78%) |
aStatistics presented: n (%); median (IQR).
bStatistical tests performed: chi-square test of independence; Kruskal–Wallis test.